Enfusion, Inc. (NYSE:ENFN – Get Free Report) saw a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 1,180,000 shares, a drop of 22.4% from the October 15th total of 1,520,000 shares. Approximately 2.4% of the shares of the company are short sold. Based on an average daily volume of 381,300 shares, the short-interest ratio is presently 3.1 days.
Enfusion Trading Down 0.9 %
Shares of Enfusion stock opened at $9.79 on Friday. The firm has a fifty day simple moving average of $9.00 and a 200-day simple moving average of $8.86. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of 244.81, a PEG ratio of 3.66 and a beta of 0.93. Enfusion has a 1-year low of $7.52 and a 1-year high of $10.45.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new position in Enfusion during the first quarter worth $44,000. RiverPark Advisors LLC bought a new position in shares of Enfusion during the 2nd quarter worth about $68,000. Arizona State Retirement System acquired a new position in shares of Enfusion during the second quarter valued at about $86,000. Price T Rowe Associates Inc. MD acquired a new stake in Enfusion during the first quarter worth about $102,000. Finally, Quadrature Capital Ltd bought a new position in Enfusion during the first quarter valued at about $109,000. Institutional investors and hedge funds own 81.05% of the company’s stock.
Enfusion Company Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Featured Stories
- Five stocks we like better than Enfusion
- What to Know About Investing in Penny Stocks
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Insider Trading – What You Need to Know
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What does consumer price index measure?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.